In this study, we analyzed 80 pan-cancer cases that underwent comprehensive genomic testing and compared the auto-classified variant tiers among four globally-available software solutions for variant interpretation from Roche, SOPHiA GENETICS, QIAGEN, and Genoox.
Read MoreAnthony Magliocco, CEO of Protean has been featured in the December Member Spotlight for the Florida Society of Pathologists.
Read MoreProtean congratulates Roy Khalife and Saar Peles on their research, presented at AMP 2023.
Read MoreDr. Magliocco will be speaking at Future of Cancer Care on November 9th!
Read MoreProtean has partnered with Aventa to bring the Aventa FusionPlus test to patients
Read MoreProtean’s new partnership with Travera will bring expanded treatment options to advanced carcinoma patients and their physicians
Read More
